BeOne Medicines Ltd. (ONC) stock
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302571% above fair value
$403.60−9.66 (-2.34%)
Close on Nov 18, 2026Market cap $45.89BP/E 72.2Yield –
BeOne Medicines r&d expenses
Research and development expenses are spending on new products and technology.
BeOne Medicines's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.29B, up 12.1% year over year. For fiscal 2025 it was $2.15B, up 9.9% from the year before. Over ten years it grew 43.4% a year on average. The highest annual figure on record is $2.15B in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.15B | +9.9% |
| FY2024 | Dec 31, 2024 | $1.95B | +9.8% |
| FY2023 | Dec 31, 2023 | $1.78B | +8.4% |
| FY2022 | Dec 31, 2022 | $1.64B | +12.4% |
| FY2021 | Dec 31, 2021 | $1.46B | +12.7% |
| FY2020 | Dec 31, 2020 | $1.29B | +39.6% |
| FY2019 | Dec 31, 2019 | $927.34M | +36.6% |
| FY2018 | Dec 31, 2018 | $679.01M | +152.4% |
| FY2017 | Dec 31, 2017 | $269.02M | +174.4% |
| FY2016 | Dec 31, 2016 | $98.03M | +68.3% |
| FY2015 | Dec 31, 2015 | $58.25M | +166.4% |
| FY2014 | Dec 31, 2014 | $21.86M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $612.28M | +16.6% |
| Q1 FY2026 | Mar 31, 2026 | $541.22M | +12.3% |
| Q4 FY2025 | Dec 31, 2025 | $615.42M | +13.5% |
| Q3 FY2025 | Sep 30, 2025 | $523.66M | +5.5% |
| Q2 FY2025 | Jun 30, 2025 | $524.90M | +15.5% |
| Q1 FY2025 | Mar 31, 2025 | $481.89M | +4.6% |
| Q4 FY2024 | Dec 31, 2024 | $542.01M | +9.7% |
| Q3 FY2024 | Sep 30, 2024 | $496.18M | +9.5% |
| Q2 FY2024 | Jun 30, 2024 | $454.47M | +7.5% |
| Q1 FY2024 | Mar 31, 2024 | $460.64M | +12.7% |
| Q4 FY2023 | Dec 31, 2023 | $493.99M | +10.8% |
| Q3 FY2023 | Sep 30, 2023 | $453.26M | +6.3% |
| Q2 FY2023 | Jun 30, 2023 | $422.76M | +11.8% |
| Q1 FY2023 | Mar 31, 2023 | $408.58M | +4.8% |
| Q4 FY2022 | Dec 31, 2022 | $446.02M | +3.6% |
| Q3 FY2022 | Sep 30, 2022 | $426.36M | +21.1% |
| Q2 FY2022 | Jun 30, 2022 | $378.21M | +6.2% |
| Q1 FY2022 | Mar 31, 2022 | $389.92M | +21.6% |
| Q4 FY2021 | Dec 31, 2021 | $430.49M | +21.1% |
| Q3 FY2021 | Sep 30, 2021 | $351.94M | +0.8% |
| Q2 FY2021 | Jun 30, 2021 | $356.09M | +24.5% |
| Q1 FY2021 | Mar 31, 2021 | $320.73M | +5.4% |
| Q4 FY2020 | Dec 31, 2020 | $355.54M | +25.5% |
| Q3 FY2020 | Sep 30, 2020 | $349.07M | +47.3% |
| Q2 FY2020 | Jun 30, 2020 | $285.97M | +25.0% |
| Q1 FY2020 | Mar 31, 2020 | $304.30M | +70.6% |
| Q4 FY2019 | Dec 31, 2019 | $283.26M | +10.0% |
| Q3 FY2019 | Sep 30, 2019 | $236.97M | +60.6% |
| Q2 FY2019 | Jun 30, 2019 | $228.76M | +39.3% |
| Q1 FY2019 | Mar 31, 2019 | $178.35M | +62.6% |
| Q4 FY2018 | Dec 31, 2018 | $257.46M | +181.9% |
| Q3 FY2018 | Sep 30, 2018 | $147.59M | +68.4% |
| Q2 FY2018 | Jun 30, 2018 | $164.25M | +247.7% |
| Q1 FY2018 | Mar 31, 2018 | $109.70M | +156.5% |
| Q4 FY2017 | Dec 31, 2017 | $91.34M | +215.7% |
| Q3 FY2017 | Sep 30, 2017 | $87.66M | +191.2% |
| Q2 FY2017 | Jun 30, 2017 | $47.25M | – |
| Q1 FY2017 | Mar 31, 2017 | $42.77M | – |
| Q4 FY2016 | Dec 31, 2016 | $28.93M | – |
| Q3 FY2016 | Sep 30, 2016 | $30.11M | – |
See a number that looks wrong?